Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

New Collaboration Designed to Advance Cancer Drug R&D

By Ryan Bushey | October 12, 2017

A novel public-private partnership could hold the key to creating the next generation of potent oncology therapies.

The National Institutes of Health (NIH) in conjunction with 11 biopharmaceutical firms announced a new initiative called the Partnership for Accelerating Cancer Therapies (PACT), which is a five-year research collaboration totaling $215 million as part of the Cancer Moonshot.

PACT’s initial focus will be on identifying, developing, and validating biomarkers to help move forward development of new immunotherapy treatments.

The current crop of immunotherapies have produced dramatic responses in certain cancer cases, which is why pharmaceutical companies have dedicated substantial investment to identify promising new treatment options for these patients.

This effort will comprise enabling systematic and uniform clinical testing of these disease indicators so researchers can gain a better understanding of biological response and resistance to certain cancer therapies. Immune and other related oncology biomarkers will be integrated into future clinical trials by establishing a guideline of standard biomarkers to be tested across all different types of studies.

“A scientific and organizational challenge this complex cannot be addressed effectively by any one organization acting alone,” said Maria C. Freire, Ph.D., the President and Executive Director of the Foundation for the National Institutes of Health, in a statement. “Instead, it requires the energies and resources of public and private partners working in close collaboration.” 

Immunotherapies don’t work for all patients so developing and standardizing these biomarkers to gain deeper insight into how these drugs work could lead to new mechanisms of action that may provide a higher benefit.

“We have seen dramatic responses from immunotherapy, often eradicating cancer completely for some cancer patients,” said NIH Director Francis S. Collins, M.D., Ph.D., in a statement. We need to bring that kind of success — and hope — for more people and more types of cancers, and we need to do it quickly. A systematic approach like PACT will help us to achieve success faster.”

Other aspects of PACT include facilitating information sharing between all groups involved with the clinical trial process to better coordinate investigative approaches and limit data duplication.

Some of the companies participating in this effort include AbbVie, Amgen, Celgene Corporation, and Roche.


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE